OnCo
technologiesTechnologyPhase 3

Multi-cancer early detection (MCED)

A single blood test intended to screen for dozens of cancers at once, including ones with no screening today.

Galleri (GRAIL) detects methylation patterns and predicts tissue of origin; PMA submitted to FDA in January 2026 with an advisory committee scheduled for 23 September 2026, based on PATHFINDER 2 and the 140,000-person NHS-Galleri trial. Exact Sciences' Cancerguard launched as an LDT; Guardant Shield adds multi-cancer results. Key open question: does earlier detection reduce mortality, and at what false-positive cost?

Schematic · not to scale
Plasma · Methylation patterns → cancer signal + origin

How it works

Machine learning classifies cfDNA methylation, fragmentation, and protein biomarkers.

Strengths
  • Covers unscreened cancers (pancreatic, ovarian, liver)
  • One draw
Limitations
  • Low sensitivity for stage I
  • Mortality benefit unproven
  • Diagnostic odyssey after positive result

Products

2top

Key papers

3top

Latest papers

top
Literature trend95 papers in the last 12 months+9% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"multi-cancer early detection" OR ABSTRACT:"multi-cancer early detection" OR TITLE:"multicancer early detection" OR ABSTRACT:"multicancer early detection" OR TITLE:"MCED" OR ABSTRACT:"MCED"). Results are unfiltered search hits about Multi-cancer early detection (MCED), not a curated reading list.

Connected

62top

cancers

4

fronts

2

technologies

8

drugs

2

companies

5

institutions

4

pathways

1

terms

6

trials

3

roadmaps

3

ideas

17

people

2

bottlenecks

2

key papers

3